Vemurafenib

Vemurafenib (INN, marketed as Zelboraf) is an inhibitor of the B-Raf enzyme developed by Plexxikon (now part of Daiichi-Sankyo) and Genentech for the treatment of late-stage melanoma.[1] The name "vemurafenib" comes from V600E mutated BRAF inhibition. Contents 1 Approvals 2 Mechanism of action 2.1 Resistance 3 Clinical trials 3.1 Side effects 4 References 5 Further reading 6 External links Approvals Vemurafenib received FDA approval for the treatment of late-stage... [wikipedia]